Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19

Rhea-AI Summary

Relief Therapeutics (OTCQB: RLFTF) reported a safety update from NRx Pharmaceuticals regarding ZYESAMI(TM) (aviptadil) in the NIH-sponsored ACTIV-3 study. This drug is in late-stage clinical testing for respiratory deficiency due to COVID-19. Relief is also advancing its pipeline through a collaboration with Acer Therapeutics to develop ACER-001 for Urea Cycle Disorders. Recent acquisitions have diversified its portfolio, enhancing the company’s market position. Relief is committed to providing therapeutic relief from serious diseases.

Positive

• Positive safety report for ZYESAMI(TM) (aviptadil) in NIH-sponsored study.
• Collaboration with Acer Therapeutics for ACER-001 development.
• Recent acquisitions expanding the pipeline and market potential.

Negative

• None.

GENEVA, SWITZERLAND / ACCESSWIRE / August 19, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP) (" NRx ") provided a safety update on ZYESAMI(TM) (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health (NIH). The related NRx press release can be accessed through the following link .

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100 ^TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,

in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH bring a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com . Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether NeuroRx will provide Relief with the data from its Phase 2b/3 study, (ii) whether aviptadil will ever be approved in the UK or the EU for the treatment of respiratory failure in critically ill patients with COVID-19, and (iii) those risks discussed in Relief's filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/660462/Relief-Reports-that-its-US-Collaboration-Partner-has-Announced-a-Positive-Safety-Report-for-ZYESAMITM-aviptadil-in-NIH-Sponsored-ACTIV-3-Study-in-Patients-with-Life-Threatening-COVID-19

FAQ

What is the recent safety update reported by Relief Therapeutics on ZYESAMI(TM)?

Relief Therapeutics reported a positive safety update from its U.S. partner NRx Pharmaceuticals for ZYESAMI(TM) (aviptadil) in the NIH-sponsored ACTIV-3 study.

How is ZYESAMI(TM) (aviptadil) being tested?

ZYESAMI(TM) (aviptadil) is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.

What collaboration has Relief Therapeutics entered into recently?

Relief Therapeutics entered a Collaboration and License Agreement with Acer Therapeutics for the worldwide development of ACER-001.

What is the purpose of ACER-001?

ACER-001 is a formulation intended for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.

How does the recent acquisition impact Relief Therapeutics?

The recent acquisitions enhance Relief Therapeutics' pipeline, providing a diverse range of marketed and development-stage programs.